By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel is divided on UnitedHealth's outlook, with concerns about the regulatory overhang on Medicare Advantage (MA) risk-adjustment payments outweighing the recent strong quarterly results.
Risk: The DOJ and Senate investigations into billing practices and the potential for a clawback of past revenue or a change in coding protocols, which could permanently compress EPS.
Opportunity: None identified as the panel is focused on risks.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
UnitedHealth's costs came in lower than expected in its most recent quarter.
The company soundly beat expectations on its top and bottom lines.
Investigations into its billing practices, however, remain ongoing.
Shares of UnitedHealth Group (NYSE: UNH) have been jumping recently after the company posted some impressive quarterly results. For a company that's been on the wrong side of analyst expectations for a while, it's welcome news for frustrated investors, who have experienced significant losses over the past few years.
But investing is based on the long term, and how a company did during its most recent three-month period is not necessarily indicative of where it may be heading in the future. Is it a good idea to invest in UnitedHealth Group today, and has it done enough to prove that it's a safe stock to own?
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
A big problem for health insurance companies in recent years has been rising costs. Utilization rates are up, and that's led to higher-than-typical costs. A key metric for UnitedHealth is the medical benefit ratio, which is how much it pays for medical expenses in relation to the premiums it collects. This past quarter, analysts expected the rate to be at 85.5%, and it came in at 83.9%, which was lower than what it was a year ago -- 84.8%.
The reduced costs enabled UnitedHealth to post better-than-expected profits, as its adjusted earnings per share for the quarter were $7.23, well below expectations of $6.57. Its revenue also totaled $111.7 billion, which was higher than the $109.6 billion that Wall Street was estimating.
The big question, however, is whether UnitedHealth can build off these results and prove that the strong quarter wasn't an anomaly. Poor performances in the past are a big reason why the stock has been an underwhelming buy. Last year, shares of UnitedHealth crashed by 35%.
Although UnitedHealth's recent results were encouraging, investors may still want to tread cautiously here. There are, after all, investigations going on into its billing practices.
Senator Chuck Grassley of Iowa has been particularly worried about the company's Medicare Advantage operations. Based on an investigation he launched, a report found that UnitedHealth has been using "aggressive strategies" to boost risk adjustment scores, which can lead to greater revenue.
If the government imposes restrictions or tighter regulations that impact the way UnitedHealth conducts its operations, that can have a drastic impact on the business, at a time when its financial position isn't looking as strong as it once was. That's why, while it may be tempting to jump on the bandwagon, I'd take a wait-and-see approach with the healthcare stock, as it still has a long way to go in proving that it's a safe buy.
Before you buy stock in UnitedHealth Group, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and UnitedHealth Group wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $498,522! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,276,807!
Now, it’s worth noting Stock Advisor’s total average return is 983% — a market-crushing outperformance compared to 200% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of April 26, 2026. *
David Jagielski, CPA has no position in any of the stocks mentioned. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"The recent MBR improvement is a temporary relief, but the stock's valuation remains vulnerable to structural regulatory changes in Medicare Advantage billing."
The article’s focus on the medical benefit ratio (MBR) improvement is a tactical distraction from the structural risk in UNH’s Optum division. While the 83.9% MBR beat is impressive, it represents a reversion to mean rather than a fundamental shift in utilization trends. The real issue is the regulatory overhang on Medicare Advantage (MA) and the potential for a permanent compression in risk-adjustment payments. UNH is trading at roughly 18x forward earnings, which assumes a return to historical margin stability. If the DOJ and Senate investigations into billing practices lead to a clawback of past revenue or a change in coding protocols, that multiple is unsustainable. I am neutral until we see the impact of 2025 CMS rate updates on actual cash flows.
If the market has already priced in the regulatory 'worst-case' scenario, UNH’s massive scale and data-driven clinical efficiency make it the only player capable of maintaining margins while smaller insurers buckle under the same compliance costs.
"The MBR compression to 83.9% indicates a durable reversal in utilization trends, de-risking UNH's near-term profitability trajectory."
UNH's Q1 crushed with MBR at 83.9% (vs 85.5% expected, down from 84.8% YoY), proving utilization pressures easing faster than feared—key for insurers as premiums lag costs. Revenue hit $111.7B (beat $109.6B est) and adj EPS $7.23 topped $6.57 (article's 'below' is an obvious typo for 'above'). Post-35% 1Y drop, this inflects momentum vs prior misses. Grassley MA probe lingers but yields no fines yet; chronic Washington noise, not acute risk. Validates buy-the-dip at depressed levels vs healthcare peers.
If Grassley's investigation escalates to fines or MA risk-adjustment curbs, it could slash billions in revenue, negating the MBR gains amid weakening balance sheet.
"One quarter of cost normalization doesn't offset the existential risk of Medicare Advantage regulatory clawback, which the article treats as peripheral rather than central to valuation."
UnitedHealth's beat looks real on the surface—83.9% medical benefit ratio vs. 85.5% expected is material—but the article conflates one quarter of cost normalization with structural improvement. The bigger red flag: Senator Grassley's investigation into Medicare Advantage risk-adjustment 'aggressive strategies' isn't a regulatory sideshow, it's existential. MA represents ~40% of UNH's profits. If CMS tightens risk scoring or penalizes retroactively, the earnings beat evaporates. The stock crashed 35% last year for a reason. One good quarter after years of misses doesn't erase the regulatory overhang or prove the cost environment has stabilized.
If the MBR improvement reflects genuine operational discipline (better claims management, network optimization) rather than transient luck, and if regulators move slowly enough that UNH can adjust before penalties, the stock could re-rate substantially on normalized earnings power.
"Regulatory risk from MA risk adjustment investigations could erode margins and offset near-term upside, making the rally fragile."
UnitedHealth delivered a strong quarter: MBR at 83.9% (vs 85.5% expected), adj EPS $7.23, revenue $111.7B vs $109.6B. That looks solid, but the bull case rests on ongoing cost leverage and favorable mix. The real risk is Medicare Advantage billing investigations; Grassley's scrutiny around risk-adjustment scores could invite stricter enforcement or penalties. If scrutiny broadens or settlements are costly, earnings power could erode. Also, the beat may reflect temporary tailwinds (utilization rebound, premium growth) rather than durable improvements. The stock's risk-reward may be less attractive than it appears given regulatory exposure.
The investigations are not proven yet, and outcomes could be modest with limited penalties; moreover, any MA risk-adjustment changes may be incremental, leaving much of the upside priced in.
"The Medicare Advantage risk-adjustment investigation represents a structural earnings risk that cannot be dismissed as mere political noise."
Grok, you are dangerously dismissive of the Grassley probe. You characterize it as 'chronic noise,' but you ignore the shift in the political climate regarding MA overpayment. The DOJ's increased focus on False Claims Act litigation against MA plans is not just 'noise'—it is a direct threat to the risk-adjustment revenue that pads UNH’s margins. Even if the MBR improves, a structural reduction in coding intensity will permanently compress EPS, regardless of operational efficiency.
"Cyberattack fallout in Optum is the overlooked drag versus hyped regulatory noise."
Everyone hyperfocuses on Grassley probe as existential, but ignores UNH's $109B cash flow war chest (TTM) enabling buybacks ($10B auth'd) and M&A insulation. Probes recur cyclically without material fines (last big settlement 2017, $2.5B across industry). Real unpriced risk: Change Healthcare cyberattack lingering costs ($1.6B Q1 hit), delaying Optum recovery amid talent exodus.
"Cash reserves don't hedge against retroactive revenue clawbacks tied to the core MA profit engine."
Grok conflates balance sheet strength with regulatory insulation—they're not the same. A $109B cash flow war chest doesn't protect against a DOJ False Claims Act settlement that could force retroactive repayment of risk-adjustment revenue, not just fines. The 2017 settlement was pre-MA-dominance; the current probe targets the mechanism that generates 40% of UNH's profits. Buyback authorization becomes irrelevant if CMS claws back billions in prior-year coding intensity.
"Retroactive MA risk-adjustment clawbacks and faster CMS tightening could erode earnings power despite the MBR beat."
Speculative: Grok's 'buy-the-dip' view ignores the timing and magnitude of potential MA risk-adjustment clawbacks, which could re-rate earnings power well beyond the quarter's beat. The cash war chest helps, but it doesn't shield free cash flow from retroactive deductions or persistent coding-intensity reductions. If 2025 CMS updates bite MA payments or tighten data rules faster than expected, the forward multiple re-pricing could overshadow near-term momentum.
The panel is divided on UnitedHealth's outlook, with concerns about the regulatory overhang on Medicare Advantage (MA) risk-adjustment payments outweighing the recent strong quarterly results.
None identified as the panel is focused on risks.
The DOJ and Senate investigations into billing practices and the potential for a clawback of past revenue or a change in coding protocols, which could permanently compress EPS.